Calliditas Therapeutics AB (publ)

SSE:CALTX.ST

107.8 (SEK) • At close February 20, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) SEK.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q1
Revenue 559.78295.481451.561294.592269.384191.352429.042260.05664.04749.73431.18198.167000.4000.47446.5860138.243000000000
Cost of Revenue 53.44814.01222.29914.92114.2149.0287.8794.3222.3850.61400000000000000000000
Gross Profit 506.332281.469429.262279.671255.17182.324421.163255.73461.66249.1231.18198.167000.4000.47446.5860138.243000000000
Gross Profit Ratio 0.9050.9530.9510.9490.9470.9530.9820.9830.9630.98811001001101000000000
Reseach & Development Expenses 120.715150.613106.677179.90688.986126.653102.239102.87796.29113.343100.29192.09875.0290.07773.99264.88748.38654.10641.70946.18631.19130.7434.17224.0551031.03327.1577.7739.5177.239
General & Administrative Expenses 166.831102.01894.62488.66877.15172.54881.02871.00358.90748.53281.07264.284.37239.353041.03718.79718.009010.29518.9969.80144.77131.3418.54638.48940.57417.52915.47411.09
Selling & Marketing Expenses 252.985240.147198.542170.502191.472167.224191.887116.135113.27293.89770.63831.17158.36819.4260000010.29518.9969.80107.2988.5587.4690000
SG&A 419.816342.165293.166259.17268.623239.772272.915187.138172.179142.429151.7195.37284.37258.77963.88141.03718.79718.00923.7910.29518.9969.80144.77131.3418.54638.48940.57417.52915.47411.09
Other Expenses -2.6960000013.5141.9463.0381.714-4.7732.8410.0071.9250.969-1.033-0.6210.685-1.01-3.8432.642.1830.689-0.067-0.339-0.2320.11-0.0550.013-0.081
Operating Expenses 540.531485.295399.843439.243330.342366.425388.668291.961271.507257.486253.313190.311159.399150.781136.341104.89166.56272.864.48952.63852.82742.72445.4631.27318.20738.25740.68417.47415.48711.009
Operating Income -34.199-203.82629.419-159.573-75.172-184.101-12.362-36.227-209.844-208.367-222.1337.856-159.398-150.781-135.941-104.891-66.562-72.326-18.043-52.63885.386-42.724-44.745-31.273-18.207-38.257-40.539-17.474-15.487-11.009
Operating Income Ratio -0.061-0.690.065-0.542-0.279-0.962-0.029-0.139-3.276-4.19-7.1240.0400-339.85300-152.586-0.38700.618000000000
Total Other Income Expenses Net -8.462-43.498-43.675-4.5094.512-23.91822.42820.26917.754-3.0673.666-1.376-5.81414.607-37.332-33.0515.3038.649-4.932.499-2.2190.1680.521-0.130.0220.02-0.005-0.905-0.624-0.751
Income Before Tax -42.661-247.324-14.256-164.082-70.66-208.01910.066-15.958-192.09-211.434-218.4676.48-165.212-136.174-173.273-137.942-61.259-63.677-22.973-50.13983.167-42.556-44.224-31.403-18.185-38.237-40.544-18.379-16.111-11.76
Income Before Tax Ratio -0.076-0.837-0.032-0.557-0.262-1.0870.023-0.061-2.999-4.251-7.0070.03300-433.18300-134.34-0.49300.602000000000
Income Tax Expense 4.817-1.1644.1124.27621.274-20.49413.747-6.8480.339-4.3870.1990.031-2.14-9.3050.1750.080.0670.0380.077-0.0130.017-0.0130.441000.023-0.041000.081
Net Income -47.478-246.16-18.368-168.357-91.934-187.525-3.681-9.11-192.429-207.047-219.176.449-159.84-125.455-170.431-138.022-61.326-63.715-23.05-50.13983.167-42.556-44.224-31.403-18.185-38.237-40.544-18.379-16.111-11.76
Net Income Ratio -0.085-0.833-0.041-0.571-0.341-0.98-0.009-0.035-3.004-4.163-7.0290.03300-426.07800-134.42-0.49500.602000000000
EPS -0.88-4.59-0.34-3.14-1.71-3.49-0.069-0.17-3.62-3.95-4.190.13-3.2-2.51-3.42-2.77-1.5-1.65-0.3-1.32.36-0.6-0.63-0.45-0.54-1.15-0.61-0.6-0.55-0.18
EPS Diluted -0.88-4.59-0.34-3.14-1.71-3.49-0.069-0.17-3.62-3.95-4.190.13-3.2-2.51-3.41-2.77-1.5-0.96-0.3-1.32.35-0.6-0.63-0.42-0.54-1.15-0.61-0.6-0.55-0.18
EBITDA -31.503-203.82629.419-159.572-75.173-180.07532.495-36.227-209.845-208.366-222.1337.856-159.399-150.781-135.941-104.891-66.562-72.326-22.2-52.63885.416-42.724-44.291-31.26-18.195-38.221-40.567-17.462-15.474-10.915
EBITDA Ratio -0.056-0.690.065-0.542-0.279-0.9410.076-0.139-3.276-4.19-7.1240.0400-339.85300-152.586-0.47700.618000000000